Binding molecules to CD38 and PD-L1
US11505616B2 · kind B2 · utility
0Cited by
5References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 27, 2017 |
| Grant date | Nov 22, 2022 |
| Priority date | — |
| Expiry date | Oct 31, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a bispecific molecule comprising at least one anti-CD38 domain and at leak one anti-PD-L1 domain, which are capable of simultaneous binding to CD38 and PD-L1 antigens, respectively.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.